Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. - Wikidata - wikimedia - TriplyDB

Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.

Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.

http://www.wikidata.org/entity/Q36861129

about

Evaluation of Dimebon in cellular model of Huntington's disease The excitatory neurotransmitter glutamate stimulates DNA repair to increase neuronal resiliency Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Reactive Oxygen Species: Physiological and Physiopathological Effects on Synaptic Plasticity Calpain and STriatal-Enriched protein tyrosine phosphatase (STEP) activation contribute to extrasynaptic NMDA receptor localization in a Huntington's disease mouse model Amyloid oligomer neurotoxicity, calcium dysregulation, and lipid rafts Mouse models of Huntington's disease and methodological considerations for therapeutic trials.Altered manganese homeostasis and manganese toxicity in a Huntington's disease striatal cell model are not explained by defects in the iron transport system.Aberrant calcium signaling by transglutaminase-mediated posttranslational modification of inositol 1,4,5-trisphosphate receptors Computational analysis of calcium signaling and membrane electrophysiology in cerebellar Purkinje neurons associated with ataxia.Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease.Role of inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington's disease and spinocerebellar ataxias Computational neurobiology is a useful tool in translational neurology: the example of ataxia Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington's disease treatment.Huntington's Disease and Striatal Signaling.HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity.Dantrolene is neuroprotective in Huntington's disease transgenic mouse model.Ca(2+) handling in isolated brain mitochondria and cultured neurons derived from the YAC128 mouse model of Huntington's disease Calcium Handling by Endoplasmic Reticulum and Mitochondria in a Cell Model of Huntington's Disease.Mitochondrial Ca(2+) and neurodegeneration Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment.Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model.Dysregulation of mitochondrial calcium signaling and superoxide flashes cause mitochondrial genomic DNA damage in Huntington disease.Inositol 1,4,5-tripshosphate receptor, calcium signaling, and polyglutamine expansion disorders.Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2.Ginsenosides protect striatal neurons in a cellular model of Huntington's disease.Ginsenosides and their CNS targets.Huntington's disease, calcium, and mitochondria.Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.Mutant Huntingtin and Elusive Defects in Oxidative Metabolism and Mitochondrial Calcium Handling.Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium.Determining the Roles of Inositol Trisphosphate Receptors in Neurodegeneration: Interdisciplinary Perspectives on a Complex Topic.Huntington's Disease: Calcium Dyshomeostasis and Pathology Models Calcium signaling and neurodegenerative diseases.The Emerging Role of GLP-1 Receptors in DNA Repair: Implications in Neurological Disorders.Calcium signaling and neurodegeneration.IGF-1 intranasal administration rescues Huntington's disease phenotypes in YAC128 mice.

P2860

Q21202838-35195C01-3AB6-4456-B56F-18A95A34602B Q24611547-828077A4-2D84-4E4E-9141-138CB302B152 Q24647950-5606023A-D116-4778-9FA3-F680E39C7834 Q27005950-706D46C1-7A98-4557-85A5-9C05B7995573 Q28070007-68FB48E6-B1D5-49E7-9475-34B7025ED8EB Q28265056-150B86E2-9EBD-4FC8-834E-B5BEDC6A1E15 Q28742804-A693703A-9179-46CD-B27C-8D96C3D67E4A Q30481208-5A2254C9-07AA-4E9D-9484-95D247B93108 Q34071987-C5E6B383-EFA1-45BF-9DE9-940C5B57A4A7 Q34281322-B032C024-856B-4CCC-B57F-AEB369C55B0F Q34306449-4FB12F9F-143C-49F1-8D4D-E1B77E1B1DAB Q34606186-F1AEB09F-07FA-4022-A24A-07538347261C Q34829422-BBB1B02E-4EF1-42C3-90E3-E05352A8A8BD Q34981549-35A43D3F-0313-4909-993F-CEC930D7369C Q34992022-C0BE780C-75AD-4E69-BF70-787F5C2E0D7C Q35072356-584CAECC-3771-4988-9C94-17B7B28AF666 Q35286098-CB64D6E7-A5C7-4CB1-8B63-43E716602293 Q35585297-DF8A084A-06E3-4BB9-BF4B-981FFED3FEE2 Q35605391-0158B6B5-B2AB-4A7F-8DBD-DC56B446A63C Q35893954-51A2F573-62A4-44EF-B58B-DEA8A64C544F Q35906784-A66A6316-9400-46F6-BBEE-F742BB86FF9C Q36095330-72EB77A3-C5F8-4332-B678-B995416B6668 Q36266600-28546D8E-7D82-4B43-AD8B-25C589D7096B Q36431970-41B38E71-EBAD-43DA-B417-83E07CF26C1D Q36579470-F79B0161-180B-42FE-873F-5AEF07D8174B Q37201299-5794166B-22BC-49C7-AC47-A2DD582E0C42 Q37359666-9B13A114-AE5E-4907-9407-969727BBF990 Q37473242-027A63FB-5F33-4B9F-9DB7-DDEE325FA5A7 Q37818509-17CF6244-438E-4E41-9D14-033CE4AB5AB8 Q37889820-E5B0A9D8-4790-4F31-B396-3B097E547B08 Q37930190-F23F9D6C-9473-4A76-B5B4-1BBB80C40DCF Q38458943-80A0D099-8641-4246-BFFD-DBC6F2546F6D Q38603960-158DAA0A-D704-45DE-8B2A-30BEDE3625DE Q38988539-13A9D9B1-A5C8-4234-8F23-DEFD2EB76460 Q39456024-7C332AF8-4D11-4C05-85D3-07A4309D26C0 Q39463322-48DF9F9A-B806-487C-BBCE-EE3997AFDB8E Q41661210-D6BEDBD1-DCE9-4DA6-B924-A0B69C54C4C5 Q42066419-BB0A8F25-00E9-41F4-AE85-17117C1CD540 Q45296557-76925D54-A943-4FAE-90C6-0006C7F596CD

P2860

Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.

http://www.wikidata.org/entity/Q36861129

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Full length mutant huntingtin ...... model of Huntington's disease.

@en

type

label

Full length mutant huntingtin ...... model of Huntington's disease.

@en

prefLabel

Full length mutant huntingtin ...... model of Huntington's disease.

@en

P1433

Q36861129-77CD9EBD-B7D8-4FB7-B436-86CAEF93720D

P1476

Q36861129-673C1055-1E2B-4DFD-9918-166510B3F3EB

P2093

Q36861129-3F30F6F3-E9D9-4D2D-8A90-6A74D44844DE

Q36861129-5BF3153D-740A-48BF-AE39-2BAE343BE34E

Q36861129-719D5607-A715-4B2E-9F0B-72846B16B536

Q36861129-BC63F913-0317-4F54-A7D1-2068A06870B4

Q36861129-EB439440-6809-4BE7-A82F-631F88E24DBB

P2860

Q36861129-044F2E58-F509-4D9F-AF3A-32248983B15D

Q36861129-0912ED73-0CB0-4729-8E48-DCBAC3A3DA79

Q36861129-19FB605F-6584-4BD9-847B-71E64A404D87

Q36861129-1D47E611-FA78-49D1-A666-E4C4DFFCDCF0

Q36861129-213040AD-891B-4564-9FF9-64374D3EBDE5

Q36861129-2E958FB7-34AA-4EF4-905D-60D44C7DD568

Q36861129-30CD1536-DADA-47E1-B88A-4EADD3C00F03

Q36861129-378C77E7-1148-4DBB-9496-88F3B05C8692

Q36861129-3B085F54-0886-4D4C-8D2C-E3339F6B94A7

Q36861129-3C84B778-CE59-425D-AB15-03A5FED4B862

P304

Q36861129-C75856EF-B509-4D24-8C4D-6EA6C1723027

P31

Q36861129-8C81A362-195F-4AA9-AACB-E583ECA6443C

P356

Q36861129-E6F2E80B-FDBD-4864-BE88-9AC751627A81

P433

Q36861129-CB67AC57-BEC1-4448-BD65-E316C8DCE2BD

P478

Q36861129-DC713F9B-D1AE-47D3-BED4-06A42B63CD68

P50

Q36861129-1BA74C29-482A-46B2-8629-538CD7F3FC35

P577

Q36861129-82BAAF8A-9C0B-412E-8B52-063A21F89AAD

P5875

Q36861129-EC51B71B-670A-49DE-8F78-69DF7E626170

P698

Q36861129-E1B7D4A4-719E-477E-9A65-6F1C709BD30F

P921

Q36861129-2D0C698C-F048-4B75-A700-713CDA9FADFD

Q36861129-70BF6C31-B543-4C57-80CE-90DC911D5BAA

P932

Q36861129-4D6DE966-66C6-4C69-B726-7024BB0704F3

P356

J.NBD.2008.03.010

P1433

Neurobiology of Disease

P1476

Full length mutant huntingtin ...... model of Huntington's disease

@en

P2093

Elizabeth Slow

http://www.w3.org/2001/XMLSchema#string

Hua Zhang

http://www.w3.org/2001/XMLSchema#string

Ilya Bezprozvanny

http://www.w3.org/2001/XMLSchema#string

Qin Li

http://www.w3.org/2001/XMLSchema#string

Rona K Graham

http://www.w3.org/2001/XMLSchema#string

P2860

Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease

Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease

Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95.

Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay

Upregulation of preprodynorphin and preproenkephalin mRNA expression by selective activation of group I metabotropic glutamate receptors in characterized primary cultures of rat striatal neurons.

A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo.

Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease.

P304

80-88

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NBD.2008.03.010

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Michael R. Hayden

P577

2008-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5346942

http://www.w3.org/2001/XMLSchema#string

P698

18502655

http://www.w3.org/2001/XMLSchema#string

P921

corpus striatum

Huntington disease

P932

2528878

http://www.w3.org/2001/XMLSchema#string